TEPP-46 (ML265) is an activator of pyruvate kinase M2 (PKM2) (AC50=92 nM), selective for PKM1, PKL and PKR. TEPP-46 has antitumor activity.

METHODS: Human hepatocellular carcinoma cells, HepG2, were treated with TCEP hydrochloride (100-400 µM) for 3 days, and cell viability was measured by MTT assay.
RESULTS: The viability of HepG2 was significantly reduced to 25.68% and 70.92% after treatment with 200 and 400 µM TCEP for 3 days, whereas the lowest concentration of TCEP (100 µM) did not significantly reduce the viability of HepG2 (3.44%). [1]
METHODS: Human peripheral blood mononuclear cell PBMCs were treated with TCEP hydrochloride (0.5-1 mM) for 24 h. Morphological and necrotic changes were assessed by Hoechst 33342/PI staining.
RESULTS: Necrosis was observed in cells treated with 0.5 mM of TCEP. [2]

METHODS: To investigate the neurotoxicity and its mechanism in mice, TCEP hydrochloride (10-100 mg/kg) was administered by gavage to Kunming mice once a day for 30 days.
RESULTS: Compared with the control group, the water intake of high-dose TCEP group was declined significantly, and the organ index of liver and spleen were increased significantly. In addition, the escape latency of TCEP exposed mice were longer than that in the control group in water maze test, while the total swimming course of high-dose TCEP group was elevated and the swimming time in target quadrant was obviously shortened compared with the control group. TCEP exposure can cause neurotoxicity by increasing thyroid hormones and inducing oxidative damage in mice. [3]